GOSSAMER BIO, INC. (GOSS) Operating Margin
- Operating margin · 12 months: Value -311.70%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -311.70% | Operating income / revenue. Period ending 2026-06-30. $-166.09M ÷ $53.29M × 100 ≈ -311.70% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -166.09M USD | Operating Income (Loss) |
| Revenue | 53.29M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | (m) | |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-166.09M | $53.29M | (m) | (m) | (m) | -311.70% |
| 2026-03-31 | $-178.78M | $55.54M | (m) | (m) | (m) | -321.92% |
| 2025-12-31 | $-170.73M | $48.47M | (m) | (m) | (m) | -352.23% |
| 2025-09-30 | $-160.82M | $44.05M | (m) | (m) | (m) | -365.07% |
| 2025-06-30 | $-145.62M | $40.24M | (m) | (m) | (m) | -361.91% |
| 2025-03-31 | $-54.77M | $124.59M | (m) | (m) | (m) | -43.96% |
| 2024-12-31 | $-59.92M | $114.70M | (m) | (m) | (m) | -52.24% |
| 2024-09-30 | $-72.82M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $-79.39M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $-177.78M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $-183.76M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $-189.09M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $-204.62M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $-212.19M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-218.59M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $-215.90M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $-215.54M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $-217.26M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-216.12M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $-224.55M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $-222.46M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $-232.20M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-233.96M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $-229.66M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $-226.08M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $-207.09M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-186.14M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-148.99M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-6.65M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |